Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 11, 2025 07:30 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome

-- BMI and hyperphagia reductions have been observed in patients with PWS treated with setmelanotide at Month 3 (n=8) and Month 6 (n=5); 17 of 18 enrolled patients remain on therapy -- -- Promising...
December 10, 2025 16:01 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome

BOSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with...
November 10, 2025 07:00 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025

– Phase 3 TRANSCEND trial data showed setmelanotide achieved significant BMI reductions in patients with acquired hypothalamic obesity on concomitant treatment with GLP-1 therapy – – Analysis of...
November 07, 2025 07:30 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity

-- FDA sets updated PDUFA goal date of March 20, 2026 – -- Company to hold conference today at 8:00 a.m. -- BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM),...
November 05, 2025 16:01 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals annonce le remboursement public de l'IMCIVREE® (setmélanotide) au Canada dans cinq provinces et dans le cadre du Programme fédéral des services de santé non assurés

BOSTON, 05 nov. 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq : RYTM), une société biopharmaceutique internationale axée sur la transformation de la vie des patients atteints de...
November 05, 2025 16:01 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program

BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with...
November 04, 2025 07:00 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update

-- Third quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $51.3 million -- -- December 20, 2025 PDUFA goal date set for sNDA for setmelanotide in acquired...
October 21, 2025 16:01 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

BOSTON, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with...
August 27, 2025 16:01 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

BOSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with...
August 20, 2025 16:01 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity

– U.S. Food and Drug Administration accepts sNDA for filing with priority review; sets PDUFA goal date of December 20, 2025 -- – European Medicines Agency accepts and validates submission for Type II...